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Background and objectives We sought to determine the frequency of use and association between prasugrel
and outcomes in acute coronary syndrome patients undergoing percutaneous coronary intervention (PCI) in clinical practice.
Methods PROMETHEUS was a multicenter observational registry of acute coronary syndrome patients undergoing PCI
from 8 centers in the United States that maintained a prospective PCI registry for patient outcomes. The primary end points were
major adverse cardiovascular events at 90 days, a composite of all-cause death, nonfatal myocardial infarction, stroke, or
unplanned revascularization. Major bleeding was defined as any bleeding requiring hospitalization or blood transfusion.
Hazard ratios (HRs) were generated using multivariable Cox regression and stratified by the propensity to treat with prasugrel.
Results Of 19,914 patients (mean age 64.4 years, 32% female), 4,058 received prasugrel (20%) and 15,856 received
clopidogrel (80%). Prasugrel-treated patients were younger with fewer comorbid risk factors compared with their counterparts
receiving clopidogrel. At 90 days, there was a significant association between prasugrel use and lower major adverse
cardiovascular event (5.7% vs 9.6%, HR 0.58, 95% CI 0.50-0.67, P b .0001) and bleeding (1.9% vs 2.9%, HR 0.65, 95%
CI 0.51-0.83, P b .001). After propensity stratification, associations were attenuated and no longer significant for either
outcome. Results remained consistent using different approaches to adjusting for potential confounders.
Conclusions In contemporary clinical practice, patients receiving prasugrel tend to have a lower-risk profile compared
with those receiving clopidogrel. The lower ischemic and bleeding events associated with prasugrel use were no longer evident
after accounting for these baseline differences. (Am Heart J 2017;188:73-81.)
Dual antiplatelet therapy with aspirin and an inhibitor
of the platelet P2Y12 receptor is standard therapy for
prevention of thrombotic complications after percutane-
ous coronary intervention (PCI).1,2 Significant genetic
and pharmacodynamic variability exists in response to
clopidogrel, and lower levels of platelet inhibition may be
observed in some patients leading to increased risk for
thrombotic events.3-5 This variability is overcome by
prasugrel, which demonstrated superior efficacy over
clopidogrel in the TRial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet InhibitioN
with Prasugrel–Thrombolysis In Myocardial Infarction
(TRITON-TIMI) 38.5-7 However, compared with clopido-
grel, prasugrel is associated with higher rates of major
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bleeding, particularly in elderly, low-body-weight pa-
tients, and those with prior stroke or transient ischemic
attack.7
Despite these randomized results, the prospective
observational Treatment With Adenosine Diphosphate
(ADP) Receptor Inhibitors: Longitudinal Assessment of
Treatment Patterns and Events After Acute Coronary
Syndrome (TRANSLATE-ACS) study evaluating 12,000
myocardial infarction (MI) patients undergoing PCI in
the United States did not demonstrate an association
between prasugrel and lower major adverse cardiovascu-
lar event (MACE) compared with clopidogrel.8,9 In
contrast, a retrospective analysis of acute coronary
syndrome (ACS) patients undergoing PCI (ACS-PCI) in
the Premier Healthcare Alliance claims database reported
lower readmission rates for MI or bleeding with prasugrel
compared with clopidogrel.10,11 Whether these diver-
gent results reflect differences in underlying patient
case-mix, methodological assumptions, or study design
remains unclear. This issue is clinically relevant because
the real-world application, and the putative benefit or
harm, of therapeutic interventions may not always
conform to the controlled settings of a randomized
study. This has important implications for informing
processes of care, quality, and outcomes. Accordingly,
we sought to examine the overall use and effect of
prasugrel compared with clopidogrel in a large and
contemporary registry of unselected real-world ACS
patients undergoing PCI.12,13
Methods
Population
PROMETHEUS was a retrospective cohort study includ-
ing patients presenting with ACS managed with PCI from
8 academic medical centers in the United States between
January 1, 2010 and June 30, 2013. The study period was
selected based on the approval and availability of
prasugrel in the US market in mid-2009, which allowed
for initial uptake of the drug and the need for a minimum
90-day follow-up in this population. We included adult
patients presenting across the entire spectrum of ACS
undergoing PCI with stent implantation receiving either
clopidogrel or prasugrel at the time of PCI. Patients
receiving both agents in the periprocedural period were
excluded.
The primary objective of this study was to compare the
effectiveness of a treatment strategy initiating prasugrel
relative to clopidogrel at the time of PCI in a usual care
environment from academic centers in the United States.
The selected academic centers maintain institutional
databases prospectively recording baseline and proce-
dural characteristics and clinical outcomes for PCI
patients, irrespective of clinical presentation. The partic-
ipating centers ran a query in their PCI database to
identify all patients presenting with ACS who received
prasugrel or clopidogrel during the study period. The
data elements that were abstracted conform to the
definitions used in the NCDR CathPCI registry.
Follow-up was performed at each participating center
by trained research personnel via telephone call,
in-person visit, or medical record review and occurred
either at regular intervals or during standard of care
post-PCI clinical visits. All sites confirmed that relevant
baseline and follow-up data on clinical end points up to 1
year were collected in each respective database using a
prestudy feasibility questionnaire.
To facilitate data extraction, the study investigators first
developed a prespecified extraction list of relevant baseline
and outcome variables. This list was then disseminated to
each individual site as a platform to extract the corre-
sponding elements from the database at each participating
center. After extraction, data were validated, examined for
completeness and quality by the Data Coordinating Center
at Mount Sinai, and aggregated to form one unified data set
upon which all analyses were performed. Study sponsors
(Daiichi Sankyo and Ei Lilly) had no access to patient-level
data. Details of the study organization, participating
centers, and investigators are shown in the Supplementary
Appendix (Tables S1 and S2).
End points and definitions
The prespecified primary end point was MACEs
defined as a composite of all-cause death, MI, stroke, or
unplanned coronary revascularization at 90 days from
index hospital PCI. In part, this time point was chosen
because it was not possible to monitor drug compliance
after hospital discharge and we assumed that the
adherence rate would be high, whereas the switching
rate would be low (≤10%) at 90 days vs a later time
interval (ie, 1 year). In addition, based on prior analyses
from the TRITON-TIMI 38 trial, the therapeutic effect of
Figure 1
Frequency of clinical presentation in PROMETHEUS cohort. Pie chart
displays the overall frequency and number of patients presenting with
unstable angina, NSTEMI, and STEMI in the PROMETHEUS cohort.
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prasugrel is largely evident within 90 days.14 The
secondary end points included individual components
of MACE, as well as MACE and its components at 1 year.
Exploratory analyses were also performed for the
composite outcome of all-cause death, MI, or stroke at
90 days and 1 year. The primary safety end point was
major bleeding, defined as any clinically overt hemor-
rhage requiring hospitalization or blood transfusion.
Statistical analysis
Patients were grouped according to prasugrel or
clopidogrel treatment at the time of PCI, defined as
receipt of medication 24 hours before and during the PCI
procedure in accordance with NCDR definitions. Base-
line clinical and procedural characteristics were com-
pared between the prasugrel and clopidogrel groups
using the Student t test and χ2 test and for continuous
and categorical variables, respectively. The cumulative
incidence of adverse events was calculated as a
Kaplan-Meier estimate of time to first event, and
comparisons between groups were performed using the
log-rank test. Two-tailed P values b.05 were considered
significant. Statistical analyses were performed using SAS
version 9.3 (Cary, NC) and Stata version 12.1 (College
Station, TX).
Multivariable and propensity adjustment
To evaluate the associations between treatment group
(prasugrel vs clopidogrel) and the primary outcome,
hazard ratios (HRs) were generated using Cox propor-
tional hazards regression stratified by the propensity to
receive prasugrel. Propensity scores were calculated
using a multivariable logistic regression model with the
dependent outcome as treatment with prasugrel (vs
clopidogrel). The propensity model was generated in an
iterative fashion using the method of Rosenbaum and
Rubin.15 In addition to age and sex, this model included
all baseline covariates demonstrating significant differ-
ences (P b .05) between groups and additional variables
that may be plausibly related to either the outcome or
exposure. The final propensity model included the
following main effects: center, coronary artery disease
(CAD) presentation, diabetes, age, age squared, bivalir-
udin, smoking, gender, African American race, hyperten-
sion, family history of CAD, prior PCI, prior coronary
artery bypass surgery (CABG), prior peripheral arterial
disease, prior congestive heart failure, prior cerebrovas-
cular disease (CVD), stent length, stent diameter,
glycoprotein IIb/IIIa inhibitor use, hypercholesterolemia,
prior MI, estimated glomerular filtration rate, stent type,
body mass index (BMI), hemoglobin, and the following
interaction terms: center * procedural glycoprotein IIb/
IIIa inhibitor use, BMI * hemoglobin, prior CVD * prior
PCI, and prior CVD * prior CABG. The overall c statistic
for the propensity model was 0.81.
From this propensity model, each observation was
assigned a predicted probability for prasugrel treatment.
The distribution of propensity scores for the entire cohort
and each treatment group was visually examined.
Mutually exclusive strata (n = 10) were then generated
based on the propensity scores for the entire cohort, a
process that was blinded to any outcome data to avoid
bias in selection. The number of strata and their
respective cut-points were based on fulfilling previously
established criteria and adequate balance in baseline
covariates.15,16
The adjusted associations between treatment groups and
the primary MACE outcome at 90 days were calculated
using Cox proportional hazards regressionwith propensity
stratification as the primary method of analysis. In addition
to treatment (prasugrel vs clopidogrel) and study center,
covariates were included to account for residual imbal-
ances between groups and/or to adjust for important
variables related to the outcome of interest.
The following sensitivity analyses for the primary MACE
outcome were also performed: multivariable adjustment,
propensity matching,17 and inverse probability weighting
(IPW).18 A sensitivity analysis was also performed for the
primary MACE outcome by defining treatment groups as
only those patients receiving the same medication at the
time of PCI and at discharge and restricted to those with
out-of hospital MACE (as-treated analysis).
Results
The study sample included 19,914 ACS-PCI patients.
The mean age of the study population was 64.4 ±
Table I. Baseline clinical characteristics by treatment group
Prasugrel
(n = 4058)
Clopidogrel
(n = 15,856) P
Age, y 58.7 ± 10.3 65.8 ± 12.3 b.0001
Female sex, n (%) 989 (24.4) 5315 (33.5) b.0001
African American, n (%) 253 (6.2) 1872 (11.8) b.0001
BMI (kg/m2) 30.7 ± 6.2 29.7 ± 6.2 b.0001
Diabetes, n (%) 1382 (34.1) 6198 (39.1) b.0001
Diabetes on insulin, n (%) 394 (9.7) 2140 (13.5) b.0001
Hypertension, n (%) 2915 (71.8) 13,466 (84.9) b.0001
Dyslipidemia, n (%) 3220 (79.3) 13,469 (84.9) b.0001
Smoking, n (%) 1175 (29.0) 3831 (24.2) b.0001
Prior MI, n (%) 833 (20.5) 5130 (32.4) b.0001
Prior PCI, n (%) 788 (19.4) 4250 (26.8) b.0001
Prior CABG, n (%) 359 (8.8) 3074 (19.4) b.0001
Prior CVD 188 (4.6) 2197 (13.9) b.0001
Prior CHF, n (%) 567 (14.0) 3684 (23.2) b.0001
Prior PAD, n (%) 291 (7.2) 2140 (13.5) b.0001
CKD, n (%) 619 (15.3) 4994 (31.5) b.0001
Anemia, n (%) 339 (8.4) 2553 (16.1) b.0001
CAD presentation, n (%)
STEMI 773 (19.0) 2512 (15.8) b.0001
NSTEMI 1159 (28.6) 4253 (26.8) .03
Unstable angina 2126 (52.4) 9090 (57.3) b.0001
Abbreviations: CHF, congestive heart failure; PAD, peripheral artery disease; CKD,
chronic kidney disease.
Baber et al 75
American Heart Journal
Volume 188, Number 0
12.3 years and 32% were women. Of this cohort, 20%
(n = 4,058) received prasugrel and 80% (15,856) re-
ceived clopidogrel at the time of PCI. The distribution by
clinical presentation in the overall cohort is shown in
Figure 1. Unstable angina (n = 11,216; 56%) was the most
common presentation, followed by non–ST-elevation MI
(NSTEMI) (n = 5,412; 27%) with ST-elevation MI (STEMI)
least common (n = 3,285; 17%). Prasugrel use varied
across the 8 sites from a minimum of 5% to a maximum of
38%. Loss to follow-up at 90 days and 1 year was 8.4% and
17.1%, respectively.
The baseline differences between patients receiving
prasugrel and clopidogrel are shown in Table I.
Prasugrel-treated patients were younger and more often
male compared with those receiving clopidogrel. The
frequency of comorbid conditions including diabetes, prior
MI, prior CVD, chronic kidney disease, and anemia was
higher among clopidogrel-treated patients. Prasugrel was
more often used in patients with STEMI or NSTEMI,
whereas clopidogrel was used more often in the United
States. As shown in Figure 2, the frequency of prasugrel use
increased with the severity of clinical presentation with a
maximum of 24% among those presenting with STEMI.
Table II shows the procedural differences between the
2 groups. Angiographically, patients receiving prasugrel
had a lower frequency of left main stem disease,
fewer complex lesions (American College of Cardiolo-
gy/American Heart Association type B2/C) and fewer
lesions with moderate/severe calcification. In contrast,
prasugrel-treated patients received longer stents with a
greater diameter, whereas patients receiving clopidogrel
were more likely to have bare-metal stents. Patients on
prasugrel also received less bivalirudin but more glyco-
protein IIb/IIIa inhibitors for procedural antithrombotic
therapy. Figure 3 displays the frequency of prasugrel use
as a function of several established clinical or angiograph-
ic thrombotic risk factors (diabetes mellitus, troponin (+)
ACS, stent diameter b 3.0 mm, or prior MI). Although
prasugrel was used in more than 20% of patients with
none or one such risk factor, use was paradoxically
lowest (13.4%) among those with 4 thrombotic risk
factors.
Unadjusted MACE rates at 90 days were 5.7% and 9.6%
among those receiving prasugrel and clopidogrel, respec-
tively (Table III and Figure 4; P b .001). Associations
were attenuated and no longer statistically significant
after adjusting for the propensity to receive prasugrel (HR
0.89, 95% CI 0.76-1.05, P = .16). The adjusted point
estimates were concordant using different analytic
methods (propensity matching, IPW, and covariate
adjustment, respectively). Inverse probability weighting
gave a less precise estimate, likely due to undue
influence of a few patients with very large weights.
Associations for most other end points at 90 days
followed a similar pattern, with large and significant
unadjusted reductions attenuating to more modest
differences after adjustment.
At 365 days, reductions in MACE associated with
prasugrel use were slightly larger in magnitude compared
with those observed at 90 days (Table III and Figure 4)
and remained significant after propensity stratification
(HR for MACE 0.86, 95% CI 0.77-0.96). In contrast, no
significant differences were observed between groups for
both MI and bleeding at 365 days.
Results for the exploratory outcome of death, MI, or
stroke demonstrate significant reductions associated with
prasugrel use at 90 and 365 days using propensity
stratification and covariate adjustment. In contrast,
results were nonsignificantly different for this outcome
using IPW (Table III).
Figure 2
Frequency of prasugrel use by clinical presentation. Bar graph depicts the frequency of prasugrel use according to clinical presentation.
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Supplementary Table III shows the results after
including those patients receiving the same medication
at the time of PCI and at hospital discharge (as-treated
analysis). These results demonstrate comparable results
to those obtained in the overall population with
unadjusted reductions in risk associated with prasugrel
use diminishing upon adjustment.
Discussion
Salient findings from this report of prasugrel use in
contemporary clinical practice include the following: (i)
use of prasugrel was relatively uncommon in an ACS-PCI
setting despite evidence from clinical trials, although use
increased among those with troponin positive syn-
dromes; (ii) patients receiving prasugrel were younger
and highly selected with fewer comorbidities compared
with their counterparts receiving clopidogrel and the
decision to use prasugrel appears to be strongly
influenced by the warnings in the US product insert;
(iii) unadjusted risks for both ischemic and bleeding
complications were substantially lower among those
receiving prasugrel compared with clopidogrel; and (iv)
differences in adverse events were attenuated and no
longer significant at 90 days after adjusting for baseline
imbalances between groups. Taken together, the current
findings represent the first cohort study using real-world
data from academic medical centers across the United
States to study the use and outcome of prasugrel as
compared with clopidogrel in patients across the entire
ACS clinical spectrum undergoing PCI.
In the TRITON-TIMI 38 randomized trial, prasugrel
reduced ischemic events by 19%, albeit at an excess cost
of bleeding, among ACS patients undergoing PCI.7
Consistent with these randomized data, our results
show lower 90-day and 1-year MACE rates with prasugrel
before and after adjustment, although adjusted differ-
ences at 90 days were modest and not statistically
significant. The magnitude and direction of benefit was
largely consistent across the different analytic
approaches.
There are several possibilities that might reconcile the
divergent results between earlier randomized trial data
and our observational findings. First, the proportion of
patients who might be expected to derive the largest
benefit at 90 days from potent platelet inhibition (ie,
STEMI) comprised only 17% of the PROMETHEUS cohort,
whereas 26% of patients enrolled in TRITON-TIMI 38
presented with STEMI.7,19,20
Second, it is possible that the relatively low-risk patients
selected to receive prasugrel in a real-world setting may
not derive or even require the same degree of therapeutic
protection compared with those enrolled in randomized
trials (ie, risk/treatment paradox).21,22 Indeed, the
frequency of many clinical risk factors that are associated
with substantial thrombotic risk, including diabetes
mellitus, prior MI, and small stent diameter were
substantially lower among those treated with prasugrel
Table II. Baseline procedural characteristics by treatment group
Prasugrel
(n = 4058)
Clopidogrel
(n = 15,856) P
Multivessel disease, n (%) 1672 (41.2) 6724 (42.4) .17
PCI vessel
Left main, n (%) 84 (2.1) 583 (3.7) b.0001
LAD, n (%) 1972 (48.6) 6923 (43.7) b.0001
Circumflex, n (%) 1100 (27.1) 4794 (30.2) b.0001
RCA, n (%) 1430 (35.2) 5367 (33.9) .097
B2/C type lesion, n (%) 2848 (70.2) 10,758 (67.8) b.0001
Moderate to severe
calcification, n (%) 422 (10.4) 2349 (14.8) b.0001
Bifurcation lesion, n (%) 446 (11.0) 1676 (10.6) .38
Total stent length, mm 31.4 ± 20.2 30.50 ± 20.9 .016
Minimum stent
diameter, mm 3.01 ± 0.49 2.96 ± 0.50 b.0001
At least 1 first-generation
DES, n (%) 297 (7.3) 2495 (15.7) b.0001
At least 1 second-generation
DES, n (%) 3283 (80.9) 10,278 (64.8) b.0001
At least 1 BMS, n (%) 569 (14.0) 3926 (24.8) b.0001
Procedural anticoagulation
Bivalirudin, n (%) 2743 (67.6) 11,726 (74.0) b.0001
GPIIb/IIIa inhibitor, n (%) 1178 (29.0) 3388 (21.4) b.0001
LMWH, n (%) 38 (0.9) 169 (1.1) .77
Abbreviations: LAD, Left anterior descending artery; RCA, right coronary artery; DES,
drug-eluting stent; BMS, bare-metal stent; GPIIb/IIIa, glycoprotein IIb/IIIa; LMWH,
low-molecular-weight heparin.
Figure 3
Frequency of prasugrel use by number of thrombotic risk factors.
Thrombotic risk factors include presentation with troponin (+)
syndrome, diabetes mellitus, prior MI, or stent diameter b3.0 mm.
Vertical bars display the frequency of prasugrel use according to the
total number of thrombotic risk factors among patients.
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compared with clopidogrel. Moreover, although prasu-
grel use increased by clinical severity, only 24% of STEMI
patients received this agent. Such selected use of
prasugrel is consistent with the results of the prospective
TRANSLATE-ACS registry, which also showed a similar
imbalance in underlying risk factors among MI patients
treated with prasugrel compared with clopidogrel.8
Clearly, further study is needed to explore the determi-
nants of clinical decision making at the time of PCI
because our results, similar to TRANSLATE-ACS, suggest
that a more potent treatment is being used in patients
with a lower likelihood to derive meaningful benefit.8,23
Whether or not recalibrating the intensity of antiplatelet
pharmacotherapy to more closely approximate a
patient's inherent thrombotic risk is a hypothesis that
warrants further study.24
In exploratory analyses, we observed a significant 25%
reduction in the composite occurrence of all-cause death,
MI, or stroke at 90 days associated with prasugrel use, a
magnitude of benefit virtually identical to that observed
in TRITON-TIMI 38 using a similar outcome and time
point. Nevertheless, the magnitude and direction of effect
for the individual components that drove this composite
end point varied substantially, with important implica-
tions for interpreting and comparing such results across
studies. More specifically, in TRITON-TIMI 38, prasugrel
use led to significant reductions in MI, not death, whereas
in PROMETHEUS, adjusted reductions in MI at 90 and
365 days were nonsignificant. In contrast, we observed
significant reductions in all-cause mortality associated
with prasugrel use in both unadjusted and adjusted
analyses. Hence, contrasting effects on individual end
points across studies yielded similar estimates for a
composite outcome that included those very
components.
The reductions in death observed in PROMETHEUS
may be attributable to selection bias, coupled with a
modest reduction in ischemic events without concordant
excess bleeding risk. With respect to the former, it is
possible that residual or unmeasured confounding
strongly influenced the mortality point estimates because
prasugrel-treated patients were much healthier compared
with those receiving clopidogrel. In support of the latter,
it is plausible that a modest reduction in MACE risk in the
absence of bleeding harm may confer a mortality
advantage. This hypothesis remains speculative, howev-
er, because the reductions in MI and MACE were
numerically lower compared with mortality and without
statistical significance. As a result, it is unlikely that similar
findings to ours will be duplicated, because the
associations with death were observed absent a concor-
dant reduction in other ischemic events.
Unadjusted bleeding rates were also significantly lower
among prasugrel- vs clopidogrel-treated patients in our
study, findings that are consistent with TRANSLATE-ACS
and are most likely attributable to the lower-risk profile of
patients selected to receive prasugrel.8 At 1 year, the
absolute differences in bleeding rates in favor of prasugrel
in our study and TRANSLATE-ACS were 1.7% and 1.0%,
respectively.8 This suggests that prasugrel-treated pa-
tients in PROMETHEUS were somewhat healthier and at
lower risk for bleeding compared with their counterparts
in the TRANSLATE-ACS study, further supporting the
inclusion of a more selected cohort unlikely to manifest
overt bleeding risk. After adjustment, however, HRs for
bleeding were not significantly different between groups.
Table III. Crude event rates, and unadjusted and adjusted associations for adverse events
Treatment group⁎ HRs (95% CI)
Prasugrel
(n = 4058)
Clopidogrel
(n = 15,856) Unadjusted Propensity stratified† IPW Covariate adjusted
90 d
MACE, primary end point, n (%) 216 (5.7) 1415 (9.6) 0.58 (0.50-0.67) 0.89 (0.76-1.05) 0.94 (0.76-1.16) 0.94 (0.80-1.09)
Death, MI, or stroke, n (%) 101 (2.7) 1000 (6.8) 0.39 (0.31-0.47) 0.75 (0.60-0.94) 0.82 (0.61-1.11) 0.77 (0.61-0.96)
Death, n (%) 23 (0.6) 408 (2.8) 0.21 (0.10-0.30) 0.62 (0.40-0.99) 0.52 (0.3-0.94) 0.68 (0.44-1.05)
MI, n (%) 74 (1.9) 562 (3.8) 0.51 (0.40-0.64) 0.84 (0.64-1.11) 1.1 (0.76-1.55) 0.84 (0.65-1.10)
Unplanned revascularization, n (%) 138 (3.7) 586 (4.1) 0.89 (0.75-1.08) 1.06 (0.86-1.31) 1.21 (0.92-1.58) 1.05 (0.85-1.28)
Bleeding, n (%) 75 (1.9) 442 (2.9) 0.65 (0.51-0.83) 1.03 (0.78-1.36) 1.01 (0.69-1.48) 1.03 (0.79-1.35)
365 d
MACE, n (%) 433 (12.1) 2866 (20.6) 0.56 (0.50-0.62) 0.86 (0.77-0.96) 0.91 (0.79-1.06) 0.85 (0.76-0.95)
Death, MI, or stroke, n (%) 199 (5.6) 1778 (12.8) 0.42 (0.36-0.48) 0.83 (0.71-0.98) 0.89 (0.72-1.10) 0.80 (0.68-0.94)
Death, n (%) 62 (1.8) 901 (6.6) 0.26 (0.20-0.33) 0.69 (0.52-0.91) 0.63 (0.43-0.91) 0.67 (0.51-0.87)
MI, n (%) 122 (3.3) 855 (6.1) 0.54 (0.44-0.65) 0.90 (0.72-1.11) 1.13 (0.86-1.49) 0.86 (0.70-1.06)
Unplanned revascularization, n (%) 300 (8.5) 1507 (11.5) 0.74 (0.65-0.84) 0.92 (0.80-1.06) 1.00 (0.84-1.20) 0.88 (0.77-1.01)
Bleeding, n (%) 112 (3.1) 664 (4.7) 0.64 (0.52-0.78) 0.97 (0.78-1.22) 0.86 (0.63-1.18) 0.96 (0.77-1.19)
⁎ Event rates calculated as Kaplan-Meier estimates at different time points.
† Propensity stratification is the prespecified primary method of adjustment. It is based on dividing the patient population into 10 strata based on the distribution of patient propensity
score.
78 Baber et al
American Heart Journal
Month 2017
Differences in patient populations, bleeding ascertain-
ment, and/or selection bias may account for the
inconsistent results between studies. For example, we
relied on bleeding-related hospitalizations as our safety
end point, whereas bleeding was prospectively ascer-
tained and adjudicated in TRANSLATE-ACS. Therefore,
underreporting of bleeding may have biased our results to
the null. Alternatively, real-world selection for prasugrel
use may be largely driven by factors that correlate with
bleeding propensity rather than ischemic risk, resulting in
the treatment for patients both unlikely to manifest overt
harm but also not experience any meaningful benefit.25
Limitations
Among the important limitations of our study was the
observational retrospective design, thereby precluding
Figure 4
Cumulative MACEs and bleeding by treatment group. Kaplan-Meier curves displaying the cumulative rate of MACEs (composite of all-cause death,
MI, stroke, or unplanned coronary revascularization—A) and bleeding (B) by treatment group at 90 and 365 days.
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causal inferences. Although we used several statistical
methods to account for the substantial imbalances
between treatment groups, we cannot exclude the
possibility of residual or unmeasured confounders
influencing our estimates. However, our findings were
consistent in both direction and magnitude across the
different adjustment techniques. In the absence of
standard prospective data collection that was uniform
across study centers, we may have underestimated the
rates of some clinical events. Detailed data on medication
adherence, an important determinant of risk after PCI,
were not available across centers. Although we used an
early time point of 90 days for our primary analysis, we
were unable to account for therapeutic crossover and/or
compliance in the follow-up period after hospital
discharge. In addition, granular information on timing
of medication administration relative to diagnostic
angiography and PCI was not available. Although
ticagrelor was approved for use in July 2011, which
coincides with the inclusion period for our study, we
directed each center to only provide data on patients
treated with either clopidogrel or prasugrel in accor-
dance with the study aims and objectives. Although we
may have excluded certain patients treated with ticagre-
lor in the latter 2 years of the study period, administrative
data describing national trends in P2Y12 inhibitor use
during this time frame are largely consistent with our
results in that clopidogrel was the most commonly used
drug followed by prasugrel with ticagrelor used least
frequently.26,27
Conclusions
In a large, real-world cohort of ACS patients undergoing
PCI at medical centers across the United States, we
observed that prasugrel is used infrequently and in much
lower-risk patients compared with those receiving
clopidogrel. Large reductions in risk for both ischemic
and bleeding complications associated with prasugrel use
were no longer apparent after considering baseline
differences between groups. Recalibrating “real-world”
use of prasugrel to better approximate a patient's
ischemic risk may yield a more appreciable therapeutic
benefit, a hypothesis that warrants further study.
Appendix. Supplementary data
Supplementary data to this article can be found online
at http://dx.doi.org/10.1016/j.ahj.2017.02.013.
References
1. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the
management of acute coronary syndromes in patients presenting
without persistent ST-segment elevation. The task force for the
management of acute coronary syndromes (ACS) in patients
presenting without persistent ST-segment elevation of the European
Society of Cardiology (ESC). G Ital Cardiol 2012;13(3):171-228.
2. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused
update of the guideline for the management of patients with unstable
angina/non–ST-elevation myocardial infarction (updating the 2007
guideline and replacing the 2011 focused update): a report of the
American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. J Am Coll Cardiol
2012;60(7):645-81.
3. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymor-
phisms and response to clopidogrel. N Engl J Med 2009;360(4):
354-62.
4. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19
genotype and risk of adverse clinical outcomes among patients
treated with clopidogrel predominantly for PCI: a meta-analysis.
JAMA 2010;304(16):1821-30.
5. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and
CYP2C19 and cardiovascular outcomes after treatment with clopi-
dogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic
analysis. Lancet 2010;376(9749):1312-9.
6. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high
loading- and maintenance-dose clopidogrel in patients with planned
percutaneous coronary intervention: the Prasugrel in Comparison to
Clopidogrel for Inhibition of Platelet Activation and
Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circu-
lation 2007;116(25):2923-32.
7. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus
clopidogrel in patients with acute coronary syndromes. N Engl J Med
2007;357(20):2001-15.
8. Wang TY. TRANSLATE-ACS provides real-world data on prasugrel,
clopidogrel use in acute MI. Presented at TCT Late Breaking Clinical
Trials 2014; 2014.
9. Chin CT, Wang TY, Anstrom KJ, et al. Treatment with adenosine
diphosphate receptor inhibitors-longitudinal assessment of treat-
ment patterns and events after acute coronary syndrome
(TRANSLATE-ACS) study design: expanding the paradigm of
longitudinal observational research. Am Heart J 2011;162(5):
844-51.
10. Bae JPFD, Ernest FR. Assessment of 30-day rehospitalization for acute
myocardial infarction in patients with acute coronary syndrome who
received percutaneous coronary intervention: a comparative effec-
tiveness study of clopidogrel and prasugrel. Presented at the
Transcatheter Cardiovascular Therapeutics Annual Meeting, Miami,
FL; 2012.
11. Ernst F, Bae J, Lipkin C, et al. A comparison of bleeding in patients
treated with clopidogrel or prasugrel in a US hospital database. Circ
Cardiovasc Qual Outcomes 2012;5(A211).
12. Crystal S, Akincigil A, Bilder S, et al. Studying prescription drug use
and outcomes with medicaid claims data: strengths, limitations, and
strategies. Med Care 2007;45(10 Supl 2):S58-65.
13. Tyree PT, Lind BK, Lafferty WE. Challenges of using medical insurance
claims data for utilization analysis. Am J Med Qual 2006;21(4):
269-75.
14. Morrow DA, Wiviott SD, White HD, et al. Effect of the novel
thienopyridine prasugrel compared with clopidogrel on sponta-
neous and procedural myocardial infarction in the Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing Platelet
Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction
38: an application of the classification system from the universal
definition of myocardial infarction. Circulation 2009;119(21):
2758-64.
80 Baber et al
American Heart Journal
Month 2017
15. Rosenbaum PR, Rubin DB. Reducing bias in observational studies
using subclassification on the propensity score. J Am Stat Assoc
1984;79(387):516-24.
16. D'Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovas-
cular risk profile for use in primary care: the Framingham Heart Study.
Circulation 2008;117(6):743-53.
17. Austin PC. Optimal caliper widths for propensity-score matching
when estimating differences in means and differences in proportions
in observational studies. Pharm Stat 2011;10(2):150-61.
18. Cole SR, Hernan MA. Constructing inverse probability weights for
marginal structural models. Am J Epidemiol 2008;168(6):656-64.
19. MontalescotG,Wiviott SD, Braunwald E, et al. Prasugrel comparedwith
clopidogrel in patients undergoing percutaneous coronary intervention
for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind,
randomised controlled trial. Lancet 2009;373(9665):723-31.
20. Udell JA, Braunwald E, Antman EM, et al. Prasugrel versus
clopidogrel in patients with ST-segment elevation myocardial
infarction according to timing of percutaneous coronary intervention:
a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasu-
grel–Thrombolysis In Myocardial Infarction 38). JACC Cardiovasc
Interv 2014;7(6):604-12.
21. Sherwood MW, Wiviott SD, Peng SA, et al. Early clopidogrel versus
prasugrel use among contemporary STEMI and NSTEMI patients in
the US: insights from the National Cardiovascular Data Registry. J Am
Heart Assoc 2014;3(2):e000849.
22. Yan AT, Yan RT, Tan M, et al. Management patterns in relation to risk
stratification among patients with non–ST elevation acute coronary
syndromes. Arch Intern Med 2007;167(10):1009-16.
23. Bagai A, Peterson ED, Honeycutt E, et al. In-hospital switching
between adenosine diphosphate receptor inhibitors in patients with
acute myocardial infarction treated with percutaneous coronary
intervention: insights into contemporary practice from the
TRANSLATE-ACS study. Eur Heart J Acute Cardiovasc Care 2014,
http://dx.doi.org/10.1177/2048872614564082.
24. Rao SV, McCoy LA, Spertus JA, et al. An updated bleeding model to
predict the risk of post-procedure bleeding among patients undergoing
percutaneous coronary intervention: a report using an expanded
bleeding definition from the National Cardiovascular Data Registry
CathPCI Registry. JACC Cardiovasc Interv 2013;6(9):897-904.
25. Bagai A, Wang Y, Wang TY, et al. In-hospital switching between
clopidogrel and prasugrel among patients with acute myocardial
infarction treated with percutaneous coronary intervention: insights
into contemporary practice from the National Cardiovascular Data
Registry. Circ Cardiovasc Interv 2014;7(4):585-93.
26. Karve AM, Seth M, Sharma M, et al. Contemporary use of ticagrelor
in interventional practice (from Blue Cross Blue Shield of Michigan
Cardiovascular Consortium). Am J Cardiol 2015;115(11):1502-6.
27. Kim K, Lee TA, Touchette DR, et al. Contemporary trends in oral
antiplatelet agent use in patients treated with percutaneous coronary
intervention for acute coronary syndrome. J Manag Care Spec Pharm
2017;23(1):57-63.
Baber et al 81
American Heart Journal
Volume 188, Number 0
